Actively Recruiting

All Genders
NCT07403370

Olanzapine Dose Comparison for the Prevention of HER-INV: A Network Meta-Analysis

Led by Shandong Cancer Hospital and Institute · Updated on 2026-02-11

2000

Participants Needed

1

Research Sites

10 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Olanzapine is an effective antiemetic agent for preventing highly emetogenic regimens-induced nausea and vomiting (HER-INV) in patients receiving highly emetogenic regimens (HER). The optimal dose remains debated, with the standard 10 mg dose often causing significant daytime sedation. Recent evidence suggests that lower doses (2.5 mg and 5 mg) may offer comparable efficacy with improved tolerability. However, no head-to-head randomized controlled trials (RCTs) directly compare all three doses.

CONDITIONS

Official Title

Olanzapine Dose Comparison for the Prevention of HER-INV: A Network Meta-Analysis

Who Can Participate

All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Olanzapine was used to prevent nausea and vomiting in adult patients (18 years or older) with solid tumors receiving highly emetogenic chemotherapy
  • The study must be a randomized controlled trial (RCT), including conference abstracts if sufficient data are provided
  • Olanzapine dose was 2.5 mg, 5 mg, or 10 mg, added to a standard triple antiemetic regimen (NK1 receptor antagonist, 5-HT3 receptor antagonist, and dexamethasone)
  • Comparison included any two of the three olanzapine doses or placebo
  • At least one pre-specified efficacy or safety outcome was reported
Not Eligible

You will not qualify if you...

  • Patients with non-solid tumors or pediatric populations
  • Non-randomized studies, observational studies, case reports, or reviews
  • Studies using olanzapine only as rescue medication
  • Studies with overlapping patient populations (only the most recent or complete publication included)

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Department of Medical Oncology

Jinan, Shandong, China

Actively Recruiting

Loading map...

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here